Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenerative Medical Technology (RMTG) EBT Margin (2018 - 2025)

Historic EBT Margin for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to 333.47%.

  • Regenerative Medical Technology's EBT Margin fell 2436500.0% to 333.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 131.77%, marking a year-over-year increase of 764800.0%. This contributed to the annual value of 135.37% for FY2024, which is 1636700.0% up from last year.
  • Latest data reveals that Regenerative Medical Technology reported EBT Margin of 333.47% as of Q3 2025, which was down 2436500.0% from 132.73% recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's EBT Margin registered a high of 9.44% during Q1 2023, and its lowest value of 10630.36% during Q1 2021.
  • In the last 5 years, Regenerative Medical Technology's EBT Margin had a median value of 287.25% in 2023 and averaged 1335.19%.
  • Within the past 5 years, the most significant YoY rise in Regenerative Medical Technology's EBT Margin was 1051950900bps (2021), while the steepest drop was -60657500bps (2021).
  • Over the past 5 years, Regenerative Medical Technology's EBT Margin (Quarter) stood at 617.97% in 2021, then rose by 30bps to 433.93% in 2022, then skyrocketed by 34bps to 287.25% in 2023, then surged by 85bps to 42.3% in 2024, then plummeted by -688bps to 333.47% in 2025.
  • Its EBT Margin stands at 333.47% for Q3 2025, versus 132.73% for Q2 2025 and 55.62% for Q1 2025.